Knight Therapeutics Inc(GUD-T)
TSX

Today's Change
Real-Time Last Update
Day Low9.10
Day High9.22
Open:9.11
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Knight Announces Early Warning Filing Regarding Shares of Crescita
Knight to Present at the Jefferies 2026 Healthcare Conference in New York City
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
Knight Therapeutics Reports First Quarter 2026 Results
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call
Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity
Knight Amends Normal Course Issuer Bid
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
Upcoming Meeting Dates - March 2, 2026
Stocks in play: Knight Therapeutics Inc.

Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.